Home// - mRNA Based Vaccine Development
Are you sure you want to exit?
Any unsave changes will be lost.
mRNA Based Vaccine Development
Ziphius Therapeutics
Category
Risk communication & Community Engagement
Country
Belgium, Europe
Description
ZIPHIUS Therapeutics announced that they have prioritized their resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus. Ziphius Therapeutics is therefore interacting with researchers at Ghent University who recently succeeded to produce an mRNA vaccine against Zika virus. This mRNA platform could also be applicable for the development of a COVID-19 vaccine.